Abeona Therapeutics (ABEO) announced that the Centers for Medicare and Medicaid Services has established a permanent Healthcare Common Procedure Coding System J-code for ZEVASKYN gene-modified cellular sheets, the Company’s autologous gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa. The new J-code for ZEVASKYN, J3389 becomes effective on January 1, 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABEO:
- Abeona Therapeutics appoints Gow as SVP, Head of Clinical Development
- Abeona Therapeutics announces ABO-503 gene therapy for XLRS selected by FDA
- Abeona, Children’s Hospital Colorado activate newest QTC for ZEVASKYN
- Abeona Therapeutics announces employee inducement grants
- Abeona Therapeutics’ Earnings Call Highlights ZEVASKYN Success